| Balance Sheets | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Cash and cash equivalents | 4,546,140 | 4,219,099 | 1,025,987 | |
| Accounts receivable, net | 291,486 | 201,481 | 199,954 | |
| Inventory | 111,036 | 104,523 | 116,217 | |
| Prepaid expenses and other current assets | 126,961 | 175,174 | 128,975 | |
| Total current assets | 5,075,623 | 4,700,277 | 1,471,133 | |
| License agreement, net | 265,518 | 265,518 | 271,143 | |
| Total property and equipment | 540,451 | 540,452 | - | |
| Less accumulated depreciation | 506,751 | 495,265 | - | |
| Property and equipment, net | 33,700 | 45,187 | 56,677 | |
| Intangible assets, gross | - | - | 243,644 | |
| Less accumulated amortization | - | - | 41,380 | |
| Intangible asset, net | 205,985 | 206,801 | 202,264 | |
| Right-of-use assets, net | 519,302 | 562,507 | 605,289 | |
| Deferred offering costs | - | - | 1,507,794 | |
| Other assets | 23,057 | 23,057 | 23,057 | |
| Total assets | 6,123,185 | 5,803,347 | 4,137,357 | |
| Accrued dividends series e convertible preferred stock | - | 54,192 | - | |
| Derivative liability current | 0 | 0 | 143,382 | |
| Convertible notes payable current | 0 | 306,716 | 74,611 | |
| Accounts payable | 1,026,809 | 980,486 | 868,545 | |
| Accrued liabilities | 743,001 | 598,335 | 785,784 | |
| Accrued dividends series e convertible preferred stock | 121,662 | 54,192 | - | |
| Deferred revenue current | 467,033 | 450,667 | 414,871 | |
| Operating lease liability current | 192,731 | 189,649 | 175,948 | |
| Total current liabilities | 2,551,236 | 2,580,045 | 2,463,141 | |
| Convertible notes payable, net | 0 | 0 | 619,355 | |
| Derivative liabilities long-term | 0 | 0 | 543,545 | |
| Deferred revenue long-term | 32,924 | 37,055 | 41,816 | |
| Operating lease liability long term | 379,717 | 429,122 | 488,725 | |
| Total long-term liabilities | 412,641 | 466,177 | 1,693,441 | |
| Total liabilities | 2,963,877 | 3,046,222 | 4,156,582 | |
| Series e convertible preferred stock, 0.01 par value 45,000 authorized 5,228 and 0 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively liquidation preference of 6,273,600 | 1,538,608 | 204,239 | - | |
| Preferred stock value-Series DPreferred Stock | 0 | 0 | 1,016 | |
| Preferred stock value-Series CPreferred Stock | 0 | 0 | 12,040 | |
| Preferred stock value-Series BPreferred Stock | 0 | 0 | 14,715 | |
| Preferred stock value-Series A2Preferred Stock | 0 | 0 | 4,424 | |
| Preferred stock value-Series A1Preferred Stock | 0 | 0 | 6,515 | |
| Preferred stock value-Series APreferred Stock | 0 | 0 | 8,464 | |
| Common stock, 0.01 par value 50,000,000 authorized 12,251,198 and 5,442,249 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively | 122,512 | 104,430 | 54,422 | |
| Additional paid-in capital | 38,426,586 | 37,870,511 | 33,126,398 | |
| Accumulated deficit | -36,928,398 | -35,422,055 | -33,247,219 | |
| Total stockholders equity (deficit) | 1,620,700 | 2,552,886 | -19,225 | |
| Total liabilities, contingently redeemable preferred stock and stockholders equity | 6,123,185 | 5,803,347 | 4,137,357 | |
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)